Asadullina, D.D.,
Gilyazova, I.R.,
Ivanova, E.A.,
Izmailova, S.M.,
Gilyazova, G.R.,
Pavlov, V.N.,
Khusnutdinova, E.K. (2024) . Disruption of miRNA regulation may affect ccRCC immunogenicity and response to ICI
therapy, making them
Fedorova, Yu Yu,
Sagitova, A.V.,
Mingazheva, E.T.,
Faishanova, R.R.,
Zagitov, I.R.,
Andreeva, E.A.,
Nurgalieva, A.Kh.,
Khusnutdinova, E.K.,
Darvish, M.,
Prokofyeva, D.S. (2024) researched – 89.91%, despite a good response to primary
therapy, had a relapse of the disease after 7 years
and for targeted
therapy of age-associated pathologies, including malignant neoplasms. In this regard, the study
FEDOROVA, Y.Y.,
KARUNAS, A.S.,
GIMALOVA, G.F.,
KHUSNUTDINOVA, E.K.,
SAVELIEVA, O.N,
MURZINA, R.R.,
GATIYATULLIN, R.F.,
ETKINA, E.I. (2019) –60% of differences in sensitivity to
therapy in patients with BA is due to genetic variability. We studied